Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' Q4 Sales Rise 44 Percent as Profit Turns to Loss on R&D, Restructuring Costs

NEW YORK (GenomeWeb News) — MorphoSys today said fourth-quarter revenues increased 44 percent as operating expenses, coming largely from R&D, spiked 115 percent and profit turned to a loss.
 
Total receipts for the three months ended Dec. 31, 2006, increased to €14 million ($18.5 million) from €9.7 million year over year.
 
MorphoSys said operating expenses increased to €15.7 million from €7.3 million year over year. The increase “was mainly due to higher product and technology development, in addition to restructuring costs in the UK.”
 
The company posted a €100,000 loss for the quarter compared with an €800,000 profit in the year-ago period.
 
MorphoSys said it had around €66 million in cash, cash equivalents, and available-for-sale financial assets as of Dec. 31.
 
MorphoSys said it expects 2007 revenues for the MophoSys Group of between €7 million and €10 million, with roughly two-thirds coming from its Therapeutic Antibodies segment.
 
In January, MorphoSys purchased the UK antibody supplier Serotec for £20 million. The deal expanded the company’s antibody business and gives MorphoSys distribution channels in the UK, US, France, and Scandinavia.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.